Galmed's Aramchol Oral Formulation Shows 500% Increased Bioavailability in Phase 1 Study

summarizeSummary

Galmed Pharmaceuticals announced highly positive Phase 1 results for its oral Aramchol meglumine formulation, demonstrating a 500% increase in bioavailability compared to the previous version, enabling a lower, once-daily dose and potential cost reductions.

check_boxKey Events

• Enhanced Bioavailability

  The new oral formulation of Aramchol meglumine (AM) demonstrated approximately 500% greater bioavailability compared to the previous Aramchol free acid (AA) formulation in a first-in-man pharmacokinetics study.

• Improved Dosing & Compliance

  The increased bioavailability enables a lower, once-daily 400mg dose of AM, improving patient convenience and compliance for future clinical trials and potential commercialization.

• Cost Reduction & IP Protection

  This development is expected to reduce drug manufacturing costs by approximately 50% and solidifies Aramchol's intellectual property protection.

• Expanded Therapeutic Potential

  The CEO highlighted that this pivotal development positions Aramchol for broader therapeutic applications, including MASH and GI cancers, beyond its initial MASH focus.

auto_awesomeAnalysis

This 6-K reports a significant clinical advancement for Galmed's lead compound, Aramchol. The 500% increase in bioavailability for the new oral formulation (AM) compared to the free acid (AA) is a pivotal development. It allows for a lower, once-daily dose, which is crucial for patient compliance and convenience, especially for chronic conditions like MASH. Furthermore, the potential 50% reduction in drug manufacturing costs and strengthened IP protection significantly enhance Aramchol's commercial viability and market potential, extending its therapeutic applications beyond MASH to GI cancers.